rofecoxib has been researched along with Intestinal Perforation in 4 studies
Intestinal Perforation: Opening or penetration through the wall of the INTESTINES.
Excerpt | Relevance | Reference |
---|---|---|
"To update the results of a previously performed analysis of the incidence of upper GI perforations, symptomatic gastroduodenal ulcers, and upper GI bleeding (PUBs) with rofecoxib compared with non-selective NSAIDs." | 4.82 | The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. ( Bolognese, JA; Reicin, AS; Simon, TJ; Watson, DJ; Yu, Q, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Watson, DJ | 1 |
Yu, Q | 1 |
Bolognese, JA | 1 |
Reicin, AS | 1 |
Simon, TJ | 2 |
Villalba, L | 1 |
Witter, J | 1 |
Calvo, N | 1 |
Iversen, E | 1 |
Munck, LK | 1 |
Hawkey, CJ | 1 |
Jackson, L | 1 |
Harper, SE | 1 |
Mortensen, E | 1 |
Lines, CR | 1 |
2 reviews available for rofecoxib and Intestinal Perforation
Article | Year |
---|---|
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Double-Blind Method; Duodenal Ul | 2004 |
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2001 |
2 other studies available for rofecoxib and Intestinal Perforation
Article | Year |
---|---|
Rofecoxib, Merck, and the FDA.
Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug Labeling; His | 2004 |
[Intestinal side effects of COX-2 inhibitors].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colonic Diseases; Colonic Pouches; | 2006 |